Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 7/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12377852 | 0.85 | HDAC1 (0.51) | HDAC1HDAC8HDAC6PDE4BTP53 | |
| SCHEMBL6437647 | 0.84 | HDAC1 (0.48) | HDAC1HDAC8HDAC6PDE4BALDH1A1 | |
| SCHEMBL3912093 | 0.84 | HDAC1 (0.50) | HDAC1HDAC8HDAC6PDE4BALDH1A1 | |
| SCHEMBL12522679 | 0.84 | HDAC1 (0.53) | HDAC1HDAC8HDAC6PDE4BALDH1A1 | |
| SCHEMBL2868465 | 0.83 | ADRB2 (0.55) | HDAC1HDAC8HDAC6PDE4BADRB2 | |
| SCHEMBL17487352 | 0.83 | HDAC1 (0.67) | HDAC1HDAC8HDAC6PDE4BSLC6A3 | |
| SCHEMBL6386434 | 0.83 | HDAC1 (0.65) | HDAC1HDAC8HDAC6PDE4BALDH1A1 | |
| SCHEMBL6438024 | 0.83 | HDAC1 (0.52) | HDAC1HDAC8HDAC6PDE4BALDH1A1 | |
| SCHEMBL29215373 | 0.82 | PLAU (0.49) | SLC6A3TP53SLC6A2FFAR1 | |
| SCHEMBL3436219 | 0.80 | HDAC1 (0.45) | HDAC1HDAC8HDAC6PDE4BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2311830-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | AstraZeneca AB (SE) | 2011-04-20 | — | — | EP | disclosed |
| EP-1723144-B1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| US-7585881-B2 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2009-09-08 | — | — | US | disclosed |
| US-20080312246-A1 | Substituted Piperazines as Metabotropic Glutamate Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312246-A1 | Substituted Piperazines as Metabotropic Glutamate Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-7456200-B2 | Compounds | ASTRAZENECA AB (SE) | 2008-11-25 | — | — | US | disclosed |
| CN-101287722-A | Substituted piperazines as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2008-10-15 | — | — | CN | disclosed |
| EP-1919901-A1 | SUBSTITUTED PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2008-05-14 | — | — | EP | disclosed |
| US-20080045571-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080015234-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| WO-2007021573-A1 | SUBSTITUTED PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037820-A1 | Substituted piperazines as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037820-A1 | Substituted piperazines as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
| EP-1723144-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2006-11-22 | — | — | EP | disclosed |
| US-20060122397-A1 | Exhibiting an activity at metabotropic glutamate receptors (mGluRs), especially at the mGluR5 receptor; neurological disorders, psychiatric disorders, acute and chronic pain | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | disclosed |
| WO-2006014185-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2006-02-09 | — | — | WO | disclosed |
| US-20050272779-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2005-12-08 | — | — | US | disclosed |
| EP-1529045-A2 | NEW COMPOUNDS | Astra Zeneca AB (SE) | 2005-05-11 | — | — | EP | disclosed |
| US-20040152699-A1 | Compounds | ASTRAZENECA AND NPS PHARMACEUTICALS, INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004014881-A2 | '1,2,4'OXADIAZOLES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | ASTRA ZENECA AB (SE) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152699-A1 | Compounds | SDHA, CYP11B2, CYP11B1 | HDAC1 1961/4885HDAC8 3324/4885HDAC6 819/4885 |
| US-20080015234-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | GRM5, GRIK5, GRM2 | HDAC1 1030/4885HDAC8 1063/4885HDAC6 620/4885 |
| US-20060122397-A1 | Exhibiting an activity at metabotropic glutamate receptors (mGluRs), especially at the mGluR5 receptor; neurological disorders, psychiatric disorders, acute and chronic pain | GRM5, GRIK5, GRM1 | HDAC1 1084/4885HDAC8 1730/4885HDAC6 1123/4885 |
| US-20050272779-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM5, GRIK5, GRM2 | HDAC1 1030/4885HDAC8 1063/4885HDAC6 620/4885 |
| US-20080045571-A1 | ADDITIONAL HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | GRM5, GRIK5, GRM2 | HDAC1 1030/4885HDAC8 1063/4885HDAC6 620/4885 |
| US-20080312246-A1 | Substituted Piperazines as Metabotropic Glutamate Receptor Antagonists | GRM5, GRM1, GRM2 | HDAC1 970/4885HDAC8 1654/4885HDAC6 771/4885 |
| US-20070037820-A1 | Substituted piperazines as metabotropic glutamate receptor antagonists | GRM5, GRM1, GRM2 | HDAC1 970/4885HDAC8 1654/4885HDAC6 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.